HC Wainwright Issues Negative Outlook for UTHR Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at HC Wainwright dropped their Q1 2026 EPS estimates for United Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $6.77 per share for the quarter, down from their prior forecast of $6.93. HC Wainwright has a “Buy” rating and a $660.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q2 2026 earnings at $6.76 EPS and Q3 2026 earnings at $6.74 EPS.

A number of other research firms also recently weighed in on UTHR. Bank of America upped their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company raised their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Stock Performance

UTHR opened at $564.81 on Thursday. The stock’s fifty day moving average is $504.78 and its 200-day moving average is $477.55. The company has a market capitalization of $24.76 billion, a PE ratio of 20.24, a P/E/G ratio of 1.66 and a beta of 0.75. United Therapeutics has a one year low of $266.98 and a one year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $6.19 EPS.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $565.87, for a total transaction of $4,696,721.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,561,479.64. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $581.63, for a total transaction of $5,525,485.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,563,576.19. The trade was a 19.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 361,820 shares of company stock worth $182,730,910. Corporate insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC boosted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.